论文部分内容阅读
[目的]系统评价参苓白术散联合西药治疗溃疡性结肠炎(UC)的临床疗效。[方法]计算机检索中国知网(1982~2015)、万方(2001~2015)、维普(1989~2015)、读秀(1996~2015)、PUBMED(1991~2015)、PLoS公共医学科学图书馆(1991~2015)、PMC美国国家医学图书馆生命科学期刊(1991~2015)等数据库,收集参苓白术散联合西药治疗UC的随机对照试验(RCT),由2位评价者独立按照纳入与排除标准筛选文献、提取资料和评价质量后,采用RevMan5.3软件进行Meta分析。[结果]共纳入10个文献,包含884例患者。参苓白术散联合西药组在治疗UC的总有效率[OR=3.30,95%CI(2.25,4.82),P<0.01]、显效率[OR=2.02,95%CI(1.54,2.65),P<0.01]均优于对照组,有效率与对照组相近[OR=1.08,95%CI(0.78,1.50),P=0.64],无效率则低于对照组[OR=0.30,95%CI(0.21,0.44),P<0.01]。差异有显著统计学意义。漏斗图分析不对称,表明存在发表性偏倚。[结论]参苓白术散联合西药组治疗UC的疗效优于对照组。
[Objective] To systematically evaluate the clinical efficacy of Shenling Baizhu Powder combined with western medicine in the treatment of ulcerative colitis (UC). [Methods] We searched the Chinese public network (1982 ~ 2015), Wanfang (2001 ~ 2015), Weipu (1989 ~ 2015), Reading show (1996 ~ 2015), PUBMED (1991 ~ 2015), PLoS Public Medical Science Library (1991 ~ 2015), PMC National Library of Life Sciences (1991 ~ 2015) and other databases, we collected randomized controlled trials (RCTs) of Shenling Baizhu Powder combined with western medicine in the treatment of UC and were independently included and excluded by 2 evaluators Standard screening literature, data extraction and quality evaluation, the use of RevMan5.3 Meta-analysis software. [Results] A total of 10 documents were included, including 884 patients. The total effective rate of Shenling Baizhu Powder combined with western medicine group was significantly higher than that of western medicine group [OR = 3.30,95% CI 2.25,4.82, P <0.01], and the effective rate [OR = 2.02,95% CI 1.54,2.65] <0.01] were better than the control group, the effective rate was similar to the control group [OR = 1.08,95% CI (0.78,1.50), P = 0.64], and the inefficiency was lower than that of the control group [OR = 0.30,95% CI 0.21, 0.44), P <0.01]. The difference was statistically significant. Funnel diagram analysis asymmetry, indicating the existence of published bias. [Conclusion] Shenling Baizhu Powder combined with western medicine group is superior to control group in the treatment of UC.